Hypoxia Imaging for Esophageal Cancer to Guide Personalized Radiation Therapy

This is a Phase I trial evaluating the safety of personalized radiation therapy based on levels of hypoxia identified on FMISO-PET and MRI. All patients will receive a baseline FMISO positron emission tomography (PET) and MRI to identify levels of hypoxia. Patients with tumor hypoxia will receive a higher dose of radiation therapy. Subjects who do not have hypoxic tumors will be treated with the standard-of-care radiation regimen. After fraction 10 of radiation therapy, an additional MRI will be performed. If this interim MRI demonstrates little or no response (as defined in Section 6), an opt

Trial Details

NCT ID
NCT04846309
Phase
PHASE1
Sponsor
University of Utah
Status
RECRUITING
Cancer Type
Esophageal Cancer
Interventions
  • Radiation
  • FMISO PET CT
Locations (sample)
  • Salt Lake City, Utah, United States|40.76078,-111.89105

Key Eligibility Criteria

  • Male or female subject aged ≥ 18 years.
  • Esophageal cancer patient eligible to undergo either neoadjuvant or definitive chemoradiation therapy (CRT).
  • Note: Stage IV patients with limited metastatic disease burden may be eligible if CRT is recommended by the multidisciplinary team.
  • Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 2.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Esophageal Cancer Trials on Trialify →